An Open-Label, Randomized, Parallel-Group, Single-Center Study to Evaluate the Single and Multiple Dose Pharmacokinetic and Pharmacodynamic Characteristics of JNJ-28431754 (Canagliflozin) in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2014
At a glance
- Drugs Canagliflozin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- 23 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Dec 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 23 Dec 2011 Actual initiation date (Jan 2011) added as reported by ClinicalTrials.gov.